Evidence map›Paper›PMID 33817227›Full record

ArticleOpen life sciences2020

MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB.

Shufang Li, Yuping Feng, Yuxia Huang, Yu Liu, Yanxi Wang, Yan Liang, Hui Zeng, Hong Qu, Ling Wei

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Open life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Roles of noncoding RNAs in chronic obstructive pulmonary disease.Journal of translational internal medicine · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. miR-223-3p Regulates NLRP3 to Inhibit Proliferation and Promote Apoptosis of ONG Cells.Computational and mathematical methods in medicine · 2022
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shufang LiDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Yuping FengDepartment of Emergency, Gansu Provincial Third People's Hospital, 730000, Lanzhou, China.
Yuxia HuangDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Yu LiuDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Yanxi WangDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Yan LiangDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Hui ZengDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Hong QuDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Ling WeiDepartment of Respiratory Medicine, Lanzhou University Second Hospital, No. 82, Cuiyingmen, Linxia Rd, Chengguan District, 730030, Lanzhou, China.
Lanzhou University · CNLanzhou University Second Hospital · CNGansu Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a high fatality rate in men and women worldwide. Recently, microRNAs (miRNAs) have been reported to be diagnostic biomarkers and therapeutic targets in NSCLC. MiR-223-3p was proved to act as a promoter in NSCLC progression. However, the regulatory mechanism of miR-223-3p in NSCLC remains little known. This study aimed to explore the regulatory mechanism between miR-223-3p and its target gene Ras homolog family member B (RHOB) in NSCLC. The mRNA level of miR-223-3p and RHOB was measured by quantitative reverse transcription PCR. Furthermore, cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Flow cytometry was conducted to analyze cell apoptosis. Transwell assays and wound healing assay were employed to examine migration and invasion. The target relationship between miR-223-3p and RHOB was predicted by starBase online database and verified by dual-luciferase assay. The protein level of RHOB was tested by western blot. Our data suggested that miR-223-3p was upregulated in NSCLC tissues and cell lines and high level of miR-223-3p contributed to a poor survival in NSCLC patients. Knockdown of miR-223-3p exerted inhibitory effects on NSCLC cell viability, migration, and invasion and promotion effect on cell apoptosis. Furthermore, RHOB was directly targeted by miR-223-3p and constrained NSCLC progression. Moreover, knockdown of RHOB rescued the effect of anti-miR-223-3p on NSCLC progression.

Indexed as

miR-223-3pNSCLCprogressionRHOB

Identifiers

PMID33817227
PMCPMC7874547
OpenAlexW3037890681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.